EMA Authorised: Tegsedi (inotersen sodium) — Akcea Therapeutics Ireland Limited

View source ↗

Summary

Authorised: Tegsedi (inotersen sodium) by Akcea Therapeutics Ireland Limited for amyloidosis with orphan designation and accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• TEGSEDI (inotersen)

Snippet

Status: Authorised. Therapeutic area: Amyloidosis. MAH: Akcea Therapeutics Ireland Limited. Decision date: 04/06/2026. Orphan medicine. Accelerated assessment